当前位置: X-MOL 学术J. Spinal Cord Med. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
The inFlow intraurethral valve-pump for women with detrusor underactivity: A summary of peer-reviewed literature
The Journal of Spinal Cord Medicine ( IF 1.8 ) Pub Date : 2020-10-15 , DOI: 10.1080/10790268.2020.1829415
Siobhan M Hartigan 1 , Roger R Dmochowski 1
Affiliation  

Context: Detrusor underactivity (DUA) in women can result in urinary retention and the need for chronic bladder drainage management. Without a cure for urinary retention due to DUA, treatment options are focused on effective bladder drainage most often by intermittent or continuous catheter drainage. The inFlow intraurethral valve pump was FDA approved for use in women with this condition in 2014.

Methods: Using a literature search, this clinical review sought to explore the epidemiology and commonly used treatment options for women with DUA and critically examine all available studies of the inFlow urinary prosthesis.

Results: Due to a lack of effective treatments to improve detrusor function, DUA is generally considered incurable and there are limited treatment options which mostly focus on effective bladder drainage. The inFlow urinary prosthesis is a unique technology which utilizes a nonsurgically inserted urethral device for females to assist with bladder drainage due to DUA. The inFlow urinary prosthesis has been used in Europe and elsewhere for 20 years and is the subject of seven peer-reviewed clinical studies. For those that tolerate the device (about half), the inFlow urinary prosthesis has a low infection rate and side effect profile, is easy to use, and can normalize urination by returning autonomy to patients and thus improve their quality of life.

Conclusion: There is no cure for women with DUA. Bladder drainage can be managed by intermittent or continuous catheterization. Appropriately selected women interested in an alternative to catheterization may be offered an on-device trial of the inFlow urinary prosthesis.



中文翻译:


用于逼尿肌活动不足女性的 inFlow 尿道内瓣膜泵:同行评审文献摘要



背景:女性逼尿肌活动不足 (DUA) 可导致尿潴留和需要长期膀胱引流管理。由于 DUA 导致的尿潴留无法治愈,治疗方案主要集中在有效的膀胱引流上,最常见的是通过间歇性或连续性导管引流。 inFlow 尿道内瓣膜泵于 2014 年获得 FDA 批准用于患有这种疾病的女性。


方法:通过文献检索,本临床综述旨在探讨 DUA 女性的流行病学和常用治疗方案,并严格审查所有可用的 inFlow 泌尿假体研究。


结果:由于缺乏改善逼尿肌功能的有效治疗方法,DUA 通常被认为是无法治愈的,治疗选择有限,主要集中在有效的膀胱引流上。 inFlow 泌尿假体是一项独特的技术,利用非手术插入的女性尿道装置来协助 DUA 引起的膀胱引流。 inFlow 泌尿假体已在欧洲和其他地方使用了 20 年,并且是七项同行评审临床研究的主题。对于那些能够耐受该装置的人(大约一半)来说,inFlow 泌尿假体感染率和副作用较低,易于使用,并且可以通过恢复患者的自主权来使排尿正常化,从而提高他们的生活质量。


结论:患有 DUA 的女性无法治愈。膀胱引流可以通过间歇或连续导尿来管理。适当选择的对导尿替代方案感兴趣的女性可以接受 inFlow 泌尿假体的设备上试用。

更新日期:2020-10-15
down
wechat
bug